Catalyst Biosciences Inc reports results for the quarter ended in September - Earnings Summary

Gyre Therapeutics

16/11/2022 18:48

* Catalyst Biosciences Inc  CBIO.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in September.
The mean expectation of two analysts for the quarter was for a
loss of 10 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Catalyst Biosciences Inc's reported EPS for the quarter
was a
loss of 16 cents​.
    * The mean earnings estimate of analysts had risen by
about 28.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Catalyst Biosciences Inc shares had risen by 10.1% this
quarter and gained 130.9% so far this year.
    * The company reported a quarterly loss of $4.88 million.
    * Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $16.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
16 at 06:48 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.10          -0.16          Missed
 Jun. 30 2022      -0.24          -0.18          Beat
 Mar. 31 2022      -0.44          -0.46          Missed
 Dec. 31 2021      -0.59          -0.64          Missed